Eli Lilly acquires SiteOne for up to $1B to expand non-opioid pain drug portfolio
Eli Lilly is acquiring SiteOne Therapeutics for up to $1 billion to expand its pipeline of non-opioid pain medications, including the experimental Nav1.8 inhibitor STC-004, aiming to provide alternatives to addictive opioid painkillers and address chronic pain conditions.